Kobo Biotech Ltd531541Corporate

Commodity Chemicals Latest results: Jun 2024 13 quarters of data
₹4.45
MCap ₹11 Cr
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹0 Cr
Sales · Jun 2024
₹-0 Cr
Operating Profit · Jun 2024
-47.8% YoY
—
OPM % · Jun 2024
₹-1 Cr
Net Profit · Jun 2024
-8.1% YoY
₹-0.56
EPS · Jun 2024
-7.7% YoY

📝 Kobo Biotech Ltd — results explained

Quarter ended June 2024 (Q1 FY25)

Kobo Biotech Ltd reported revenue of ₹0 crore for the quarter ended June 2024 (Q1 FY25).

The company reported a net loss of ₹1 crore, against a net loss of ₹1 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.56.

Full year and trailing twelve months

For the full year FY24, Kobo Biotech Ltd posted revenue of ₹0 crore, with a net loss of ₹5 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹0 crore with a net loss of ₹5 crore.

Valuation snapshot

At the current price of ₹4.45, 531541 has a market capitalisation of ₹11 crore.

Within the Commodity Chemicals industry, it is the 25th-largest of the 50 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 44.95%, domestic institutional investors (DIIs) 0.00%, public shareholders 55.05% of Kobo Biotech Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹11 Cr
Current Price ?
₹4.5
P/E ?
N/A
Industry P/E ?
22.50
P/B ?
-0.08
P/S ?
N/A
P/FCF ?
2.54
Enterprise Value ?
₹150 Cr
EV/EBITDA ?
-151.81
PEG ?
N/A
Earnings Yield ?
-3.4%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
₹-5 Cr
EPS (TTM) ?
₹-2.11
ROCE ?
-125.6%
ROE ?
3.6%
ROA ?
-7.0%
Growth
Sales — latest qtr ?
₹0 Cr
PAT — latest qtr ?
₹-1 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
-8.1%
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
18%
Profit growth (5y) ?
12%
Financial Health
Debt ?
₹140 Cr
Debt to Equity ?
-1.01
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
44.95%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-34.9%
Return 6 months ?
88.6%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024 YoY % QoQ %
Sales 0000000000000 — —
Operating Profit -0-1-0-9-0-0-0-1-0-0-0-0-0 -47.8% -36.0%
Other Income 0000000000000 +0.0% —
Interest 0000000000000 — —
Depreciation 1111111111111 +0.0% +0.0%
Profit Before Tax -2-2-1-10-1-1-1-2-1-1-1-1-1 -9.0% -5.6%
Net Profit -2-2-1-10-1-1-1-2-1-1-1-1-1 -8.1% -5.6%
EPS -0.67-0.78-0.57-4.37-0.62-0.46-0.50-0.75-0.52-0.51-0.52-0.53-0.56 -7.7% -5.7%
OPM % — — — — — — — — — — — — — — —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY23 FY24 TTM YoY %
Sales ₹0 Cr ₹0 Cr ₹0 Cr —
Operating Profit ₹-2 Cr ₹-1 Cr ₹-1 Cr +41.7%
OPM % — — — —
NPM % — — — —
Other Income ₹0 Cr ₹0 Cr ₹0 Cr +0.0%
Depreciation ₹4 Cr ₹4 Cr ₹4 Cr +0.0%
Interest ₹0 Cr ₹0 Cr ₹0 Cr —
EBIT ₹-6 Cr ₹-5 Cr ₹-5 Cr +11.3%
PBT ₹-6 Cr ₹-5 Cr ₹-5 Cr +11.3%
Tax — — — —
Net Profit ₹-6 Cr ₹-5 Cr ₹-5 Cr +11.0%
EPS ₹-2.33 ₹-2.08 ₹-2.12 +10.7%
Material Cost — — — —
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2022Mar 2023Mar 2024Mar 2025 % Chg
Equity Capital 23.8323.8323.8323.83 +0.0%
Reserves -146.25-151.81-156.74-161.97 -3.3%
Borrowings 140.71139.84139.69139.69 +0.0%
Other Liabilities 60.8963.4764.6270.04 +8.4%
Total Liabilities 79.1875.3371.4071.59 +0.3%
Fixed Assets 41.6637.5933.5229.44 -12.2%
CWIP 0.000.000.000.00 —
Investments 0.000.000.000.00 —
Other Assets 37.5237.7437.8842.15 +11.3%
Total Assets 79.1875.3371.4071.59 +0.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2022Mar 2023Mar 2024Mar 2025 % Chg
Cash from Operating Activity 93.760.870.204.18 +1990.0%
Cash from Investing Activity 25.090.000.000.00 —
Cash from Financing Activity -120.28-0.87-0.150.00 +100.0%
Net Cash Flow -1.430.000.054.18 +8260.0%
Free Cash Flow 106.650.870.204.18 +1990.0%
CFO/OP -892%-58%-23%-337% -1365.2%

➗ Ratios (latest 4 periods)

Metric Mar 2022Mar 2023Mar 2024Mar 2025 % Chg
ROCE % -17.60%-36.82%-52.90%-125.57% -137.4%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 44.95%44.95%44.95%44.95% +0.0%
DIIs 0.00%0.00%0.00%0.00% —
Public 55.05%55.05%55.05%55.05% +0.0%
No. of Shareholders 7,9477,9707,9777,734 -3.0%

⚖️ Peer comparison

Industry: Commodity Chemicals · top 25 of 50 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 506854 TANFAC Industries ₹2,120.80 6,774 62.7 722 68 15.4% 9.4% 27.6% -20.5% 6.4% -11.3%
2 507753 TGV Sraac ₹89.93 1,096 7.3 1,950 132 17.9% 6.8% 11.5% 41.9% 4.9% 27.3%
3 530477 Vikram Thermo ₹174.50 1,050 12.5 144 44 42.0% 30.4% 7.0% 446.1% 32.4% 67.3%
4 506687 Transpek Industry ₹1,378.50 770 19.7 618 39 14.5% 6.3% -4.4% -6.3% -2.1% -42.7%
5 506808 Tuticorin Alkali ₹84.67 698 30.9 342 33 15.9% 9.8% 9.1% -41.1% 6.0% -31.8%
6 PRIMO Primo Chemicals ₹26.00 630 40.0 560 16 12.3% 2.9% 1.1% 331.6% -1.2% 14.7%
7 539195 POCL Enterprises ₹557.00 414 50.9 1,525 34 4.2% 2.2% -1.3% 23.7% 25.1% -51.0%
8 514440 Blue Pearl ₹46.44 405 — 47 1 2.7% 2.2% 41.5% 62.5% -13.1% 2.6%
9 524634 Alufluoride ₹480.45 396 15.2 192 25 22.1% 12.9% 10.7% 39.7% -39.3% -11.4%
10 500012 Andhra Petrochemicals ₹106.70 373 — 456 -16 -4.5% -3.4% -9.2% 13.5% -44.7% 109.0%
11 544205 National Peroxide ₹1,038.25 344 35.6 319 17 12.1% 5.3% 1.0% 590.7% 44.1% 642.6%
12 500449 Hindustan Organic ₹56.50 239 — 505 -2 0.2% -0.4% 6.9% -103.1% -41.5% 164.0%
13 543993 ARCL Organics ₹73.32 215 5.7 272 10 12.4% 3.8% 8.7% -57.9% -0.6% 128.5%
14 538896 Kanchi Karpooram ₹361.90 161 20.6 155 8 7.4% 4.9% -1.8% -60.9% 16.4% 113.2%
15 524336 Shree Hari ₹73.44 153 3.9 215 12 7.7% 5.5% 30.7% -17.4% 125.8% 455.0%
16 524640 Archit Organosys ₹49.30 139 13.6 145 7 10.8% 5.1% 12.2% 58.7% 11.7% -28.9%
17 524174 Kesar Petroproducts ₹17.79 135 40.4 187 4 8.8% 2.3% 1.1% -2.9% -0.8% -91.3%
18 526231 Standard Surfactants ₹63.44 115 58.7 93 1 1.5% 0.8% -44.1% -3.6% -6.5% 175.0%
19 519097 Ritesh International ₹27.26 80 4.9 182 5 4.9% 2.8% 29.5% 11.2% 44.2% 358.9%
20 506605 Polychem ₹2,750.00 73 3.6 44 30 10.1% 67.9% 5.5% 677.1% 12.7% -216.8%
21 532425 Genus Prime ₹26.28 69 9.1 4 4 85.4% 102.1% 1747.8% 10950.0% 5700.0% 20050.0%
22 524564 Gayatri BioOrganics ₹6.13 63 — — -1 — — — -54.2% — -147.1%
23 506947 Advance Petrochemicals ₹234.65 56 10.3 57 2 8.3% 3.6% -5.1% -93.3% 98.7% 20295.0%
24 526335 Shreyas Interm. ₹10.98 52 — 17 -1 -0.4% -7.5% — 20.4% — 6.7%
25 531541 Kobo Biotech ₹4.15 11 — — -5 — — — 11.0% — -8.1%
❓ Frequently asked questions
What was Kobo Biotech Ltd's revenue in Q1 FY25?
Kobo Biotech Ltd reported revenue of ₹0 crore for the quarter ended June 2024 (Q1 FY25).
What was Kobo Biotech Ltd's net profit in Q1 FY25?
The company reported a net loss of ₹1 crore, against a net loss of ₹1 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.56.
What is 531541's market capitalisation and P/E ratio?
At the current price of ₹4.45, 531541 has a market capitalisation of ₹11 crore.
Who owns Kobo Biotech Ltd? (shareholding pattern)
As of Jun 2026, promoters held 44.95%, domestic institutional investors (DIIs) 0.00%, public shareholders 55.05% of Kobo Biotech Ltd.
TTM ends 2024-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI